What is the optimal systemic treatment approach for metastatic uveal melanoma, including recommendations based on HLA‑A*02:01 status?

Metastatic Uveal Melanoma: Optimal Systemic Treatment Approach

For HLA-A*02:01-positive patients with metastatic uveal melanoma, tebentafusp should be offered as first-line systemic therapy, administered at 20 mg on day 1,30 mg on day 8, and 68 mg weekly thereafter until progression. 1

Treatment Algorithm Based on HLA-A*02:01 Status

Step 1: HLA-A*02:01 Testing

All patients with metastatic uveal melanoma require high-definition HLA typing to determine HLA-A*02:01 status before treatment selection 2. This biomarker determines eligibility for the only FDA-approved therapy with proven survival benefit.

Step 2: HLA-A*02:01-Positive Patients (45-50% of population)

Tebentafusp is the standard of care with strong evidence demonstrating:

• Median overall survival of 21.6 months versus 16.9 months with investigator's choice therapy (HR 0.68; 95% CI 0.54-0.87) 3
• 3-year survival rate of 27% versus 18% in controls 3
• Sustained survival benefit maintained at 3-year follow-up 1

Dosing schedule:

• Day 1: 20 mg IV
• Day 8: 30 mg IV
• Weekly thereafter: 68 mg IV until progression 1

Expected toxicity profile (mostly early, manageable):

• Rash (83%), pyrexia (76%), pruritus (70%), hypotension (38%)
• Most adverse events occur early during treatment
• Only 2% discontinuation rate due to adverse events
• No treatment-related deaths 3

Important caveat: Patients with rapidly progressing disease or very high tumor burden may not derive the same benefit and require individualized assessment 4.

Step 3: HLA-A*02:01-Negative Patients (50-55% of population)

No specific systemic therapy can be recommended based on current evidence. 1 The 2023 ASCO guidelines explicitly state "no recommendation for or against any specific systemic therapy may be made at this time" for this population.

Treatment options to consider (in order of preference):

1. Clinical trial enrollment (strongly preferred) 1

2. Liver-directed therapies for patients with hepatic-predominant disease:

   • Surgical resection for limited hepatic metastases
   • Isolated hepatic perfusion
   • Percutaneous hepatic perfusion
   • Chemoembolization 2, 5

3. Systemic therapy options (off-label, limited evidence):

   • Immune checkpoint inhibitors (pembrolizumab, ipilimumab, or nivolumab) - though response rates are historically poor in uveal melanoma 1
   • These agents showed no survival benefit in the control arm of the tebentafusp trial 3

Key Clinical Considerations

Why Uveal Melanoma Differs from Cutaneous Melanoma

Uveal melanoma has distinct molecular characteristics - lacking BRAF, NRAS, and KIT mutations that are targetable in cutaneous melanoma 2. The standard cutaneous melanoma regimens (BRAF/MEK inhibitors, checkpoint inhibitors) have shown limited efficacy in uveal melanoma, which is why HLA-A*02:01 status is critical for treatment selection.

Monitoring and Response Assessment

• Use RECIST criteria for response evaluation
• Consider tumor growth rate (TGR) analysis
• Circulating tumor DNA (ctDNA) dynamics may serve as surrogate biomarker - reduction in ctDNA associated with improved survival 2, 6
• Note that objective response rates with tebentafusp are low, but disease control rates are higher and correlate with survival benefit 1

Combination Approaches

Emerging data suggest potential benefit from combining tebentafusp with liver-directed therapies or radiotherapy for oligoprogressive disease 7, 8. Stereotactic body radiotherapy to progressing lesions while continuing tebentafusp may induce abscopal-like effects through enhanced T-cell recruitment 7.

Common Pitfalls to Avoid

1. Do not delay HLA typing - this should be performed at diagnosis of metastatic disease, not after progression on empiric therapy
2. Do not use cutaneous melanoma regimens as standard therapy - the molecular biology is fundamentally different
3. Do not discontinue tebentafusp for early cytokine-related toxicity - most adverse events are manageable and occur early, with improved tolerability over time 3
4. Do not assume low objective response rate means treatment failure - disease control and survival benefit occur even without RECIST responses 1

The evidence strongly supports HLA-A*02:01 testing as the critical first step, with tebentafusp representing the only systemic therapy with proven mortality benefit in this disease 1, 3.